TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05365737

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral rinse
Description: Participants use mouthwasher for a given time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral rinse
Description: Participants use mouthwasher for a given time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral rinse
Description: Participants use mouthwasher for a given time.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral rinse
Description: Participants use mouthwasher for a given time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva harvest
Description: Non-stimulated saliva harvesting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva harvest
Description: Non-stimulated saliva harvesting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva harvest
Description: Non-stimulated saliva harvesting

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saliva harvest
Description: Non-stimulated saliva harvesting
Study: NCT05665699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120
Description: increasing dose of D-0120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120
Description: increasing dose of D-0120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: standard dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: standard dosing
Study: NCT06458231

Intervention type: DEVICE
Intervention: Blood Catheters
Description: Central line as a predisposing factor for Blood stream infection

Intervention type: DEVICE
Intervention: Blood Catheters
Description: Central line as a predisposing factor for Blood stream infection

Intervention type: DEVICE
Intervention: Blood Catheters
Description: Central line as a predisposing factor for Blood stream infection
Study: NCT06209892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended anticoagulation
Description: This study plan will extend the duration of rivaroxaban 20mg in the experimental group to 12 months. The regular anticoagulation group will take the drug for 6 months
Study: NCT06182826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Stability protocol
Description: 5 Minutes Warm up Hamstring stretch Back Extensor Stretch Hip Flexor Stretch Jumping Rope Stair Stepping Mountain Climbers Curl Up Side Planks Bird Dog Frequency: 3 sessions per week for six weeks. Time Duration: Approx. 30 to 45 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine exercise therapy
Description: 5 Minutes Warm up Hamstring stretch Back Extensor Stretch Hip Flexor Stretch Jumping Rope Stair Stepping Mountain Climbers Frequency: 3 sessions per week for six weeks. Time Duration: Approx. 30 to 45 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine exercise therapy
Description: 5 Minutes Warm up Hamstring stretch Back Extensor Stretch Hip Flexor Stretch Jumping Rope Stair Stepping Mountain Climbers Frequency: 3 sessions per week for six weeks. Time Duration: Approx. 30 to 45 minutes
Study: NCT05007977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-01 low dose
Description: Single subcutaneous (SC) injection of ZT-01 3 mg during hypoglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-01 low dose
Description: Single subcutaneous (SC) injection of ZT-01 3 mg during hypoglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-01 low dose
Description: Single subcutaneous (SC) injection of ZT-01 3 mg during hypoglycemic clamp
Study: NCT04117425

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: biological collection
Description: Blood collection at each trimester of pregnancy, delivery and post partum visit or at medical interruption.~Collection of saliva at each trimester of pregnancy and post partum visit. Collection of cord blood and amniotic fluid at delivery or at medical interruption.
Study: NCT05007977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-01 low dose
Description: Single subcutaneous (SC) injection of ZT-01 3 mg during hypoglycemic clamp
Study: NCT06462079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Patients were treated with Sacituzumab Govitecan 10 mg/kg in 21-day treatment cycles with intravenous infusions on days 1 and 8 and continued until disease progression or unacceptable toxicity.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy was administered after the second infusion of Sacituzumab Govitecan, on day 9 after the start of this regimen. The radiotherapy regimen was: brain metastases at a dose of 60 Gy/20 doses. For lesions located adjacent to the brainstem and optic nerve, 54 Gy/20 doses were given. For patients with ≥5 lesions, whole-brain radiotherapy at 40 Gy/20 doses was synchronized with radiotherapy to localized brain metastases.
Study: NCT06353620

Intervention type: DIAGNOSTIC_TEST
Intervention: High Density EEG recording
Description: Recording of resting state high density EEG (128 channels)

Intervention type: DIAGNOSTIC_TEST
Intervention: High Density EEG recording
Description: Recording of resting state high density EEG (128 channels)
Study: NCT05972343

Intervention type: DEVICE
Intervention: Cryoablation
Description: Takes place at single time point.
Study: NCT05051306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-load resistance exercise
Description: Subjects in high-load trial performed 4 sets per exercise, 8 repetitions with load of 85%-8RM with 90 sec of rest between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-load resistance exercise
Description: Subjects in low-load trial performed 4 sets per exercise, 15 repetitions with load of 45%-8RM with 90 sec of rest between sets.
Study: NCT06154460

Intervention type: PROCEDURE
Intervention: Laterjet Surgery
Description: The laterjet procedure is an operation in which the coracoid process is transferred to the glenoid rim with a screw.

Intervention type: PROCEDURE
Intervention: Reimplissage Surgery
Description: Reimplissagge operation, which means to fill, is an open procedure designed to limit the engagement of Hill-Sachs deformity by passing the infraspinatus into the Hill-Sachs defect.

Intervention type: PROCEDURE
Intervention: Capsular Reconstruction
Description: Allografts or autografts are used for capsular reconstruction. In the procedure performed with capsular repair and grafts, the capsule is strengthened and stabilization is attempted
Study: NCT05322759

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aquatic exercises
Description: aquatic polymetric exercises for 30 min including hip abduction/adduction, knee flexion/extension, hip flexion/extension, holding pool from sides, bending forward and picking up objects, shoulder flexion/extension kangroo jumpes, jumping to sides.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic exercises
Description: aquatic polymetric exercises for 30 min including hip abduction/adduction, knee flexion/extension, hip flexion/extension, holding pool from sides, bending forward and picking up objects, shoulder flexion/extension kangroo jumpes, jumping to sides.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: halliwick exercise programme
Description: Halliwick exercise programme for 30 min include sagittal rotations, transversal rotations, longitudnal rotations and combined rotations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: halliwick exercise programme
Description: Halliwick exercise programme for 30 min include sagittal rotations, transversal rotations, longitudnal rotations and combined rotations.
Study: NCT04782492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: graft configuration in coronary artery bypass grafting
Description: Saphenous vein could be used as Y-composite graft or aortocoronary conduit during coronary artery bypass grafting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: graft configuration in coronary artery bypass grafting
Description: Saphenous vein could be used as Y-composite graft or aortocoronary conduit during coronary artery bypass grafting
Study: NCT05989152

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG-PET at the end of treatment for IE
Description: FDG-PET at the end of treatment for IE in patients with a prosthetic valve
Study: NCT05289414

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency
Description: patients with diagnosis of cervicogenic headache will be subjected to radiofrequency treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greater occipital nerve block
Description: patients with diagnosis of cervicogenic headache will be subjected to Greater occipital nerve block
Study: NCT04861155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIVA-P3
Description: Digital cough recording: Participants receive a small, wearable data recorder, wear it during waking hours and keep it on the nightstand during sleep for 7x24 hours. The data is sent to a smartphone application, where a cough detection algorithm converts it into time-stamped cough events. Participants respond to questions on their smartphone once a day for additional context data. The cough events and context data are sent to a secure online database for further evaluation. For the first 24 hours, segments of audio data are sent to be able to validate the performance of the cough detection algorithm. Afterwards, only cough events and context data are sent from the participant's smartphone.
Study: NCT05950373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education video
Description: six minute long education video focusing on protein and energy meals for older adults.
Study: NCT05791487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ulcerative colitis Exclusion Diet
Description: a limited whole food diet (UCED)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partial enteral nutrition (PEN)
Description: The diet will be supplemented by 3 glasses a day (750 ml) of the formula developed for UC using the UCED principles.
Study: NCT04814576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative cares
Description: The intervention consists of the co-design and implementation of therapeutic activities by the nurse and the mental health day hospital users following a collaborative care model. For this purpose, the participatory action research (PAR) method will be used and semi-structured interviews and focus groups will be used as data collection techniques.
Study: NCT05282173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Siyakhana CHW Training
Description: Please see arm description.
Study: NCT05747729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib and Serplulimab
Description: Surufatinib: Safety lead-in : Oral, QD, starting dose 250 mg, adjusted according to DLT. Dose expansion: administration according to the dose determined in the safety lead-in phase.~Serplulimab: 300 mg intravenous infusion on day 1, repeated every 3 weeks.
Study: NCT04612556

Intervention type: DRUG
Intervention: Mepolizumab 100 MG [Nucala]
Description: subcutaneous injection once a month
Study: NCT05791487

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: free diet
Description: oral Budeosnide for 6 weeks + free diet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Budesonide
Description: Oral Budesonide 9 mg
Study: NCT05542264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: SEP-363856 will be supplied as over-encapsulated tablets. Multiple tablets may be required to achieve a single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Description: PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
Study: NCT04558918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: Taken Orally b.i.d. Dosage Supplied: 200 mg Dosage form: Hard gelatin capsule Route of Administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eculizumab
Description: Administered as intravenous infusion every 2 weeks as per the stable regimen, the maintenance dose is a fixed dose.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion
Study: NCT05791487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Budesonide
Description: Oral Budesonide 9 mg
Study: NCT05457673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtaCor StealthTrac Lead
Description: Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
Study: NCT04656145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing
Description: On the day of the operation, after the procedure has concluded and the drains have been placed, the surgical drain site that has been randomized to be in the experimental group will receive the chlorhexidine gel dressing. The dressing will remain on the patient until the drain has been removed and the surgical site will be assessed for signs of infection.
Study: NCT05347550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graduated Compression Stockings - Thromboembolic deterrent stockings
Description: Centres randomised to the intervention arm will consist of participants receiving GCS.
Study: NCT05725850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EG (Experimental A. Oleracea extract gel)
Description: Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the EG received application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GP (Gel placebo)
Description: Prior to bleaching treatment with 35% hydrogen peroxide, the GP group also received the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
Study: NCT05387655

Intervention type: BIOLOGICAL
Intervention: BCG
Description: BCG vaccination

Intervention type: BIOLOGICAL
Intervention: Placebo vaccine
Description: Placebo vaccination
Study: NCT05087095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM Intervention
Description: The CALM intervention includes 6 individual therapy sessions, each approximately 45-60 minutes in length, delivered over 3 months. Participants will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~* Within one week before initiating the CALM intervention therapy~* Within one week after its completion,~* 3 months after the CALM intervention is complete~  * After each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components
Study: NCT05251545

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: Comparison of power levels in catheter ablation in regard of single procedure success rate (freedom of any atrial arrhythmia with a duration of more than 30 sec. 45 Watts versus standard power levels (30 Watts).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: Comparison of power levels in catheter ablation in regard of single procedure success rate (freedom of any atrial arrhythmia with a duration of more than 30 sec. 45 Watts versus standard power levels (30 Watts).
Study: NCT04558918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ravulizumab
Description: Administered as intravenous infusion every 8 weeks, the maintenance dose is based on body weight.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion
Study: NCT05163028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-2376
Description: SHP2 Inhibitor
Study: NCT04804410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LCR Meter (Brand: Keysight, Serial Number:E498AL)
Description: The LCR meter is used for electric property analysis of tissues. It works by measuring impedance on multiple sections of excised tissue and translating those measurement into dielectric properties.
Study: NCT05747092

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gingival graft
Description: investigators:~Donor site:~* tissue graft harvesting from the palate behind the palatal rugae .~* placement of a palatine hemostatic plaque on the palate in order to reduce the risk of bleeding and to diminish the postoperative pain.~Received site:~* Control: the horizontal incision adjacent to the recession(s) and vertical incisions and split thickness flap. Placement of the graft on the recipient bed and suture.~* Test :connective tissue graft using the  envelope/pouch  technique with two partial thickness incisions (deep and superficial). Placement of the graft inside the envelope

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gingival graft
Description: investigators:~Donor site:~* tissue graft harvesting from the palate behind the palatal rugae .~* placement of a palatine hemostatic plaque on the palate in order to reduce the risk of bleeding and to diminish the postoperative pain.~Received site:~* Control: the horizontal incision adjacent to the recession(s) and vertical incisions and split thickness flap. Placement of the graft on the recipient bed and suture.~* Test :connective tissue graft using the  envelope/pouch  technique with two partial thickness incisions (deep and superficial). Placement of the graft inside the envelope
Study: NCT06454110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 will be administered as an intravenous infusion. All subjects will be administered 17 mg/kg of NM8074 intravenously weekly for a total of 15 doses from Day 1 to Day 99 of the Treatment Period.
Study: NCT04718467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine (Sf9 cells)
Description: Three doses of Recombinant COVID-19 vaccine (Sf9 cells) (40μg) at the schedule of day 0, 21, 42.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine (Sf9 cells)
Description: Three doses of Recombinant COVID-19 vaccine (Sf9 cells) (40μg) at the schedule of day 0, 21, 42.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three doses of Placebo (1.0ml) at the schedule of day 0, 21, 42.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three doses of Placebo (1.0ml) at the schedule of day 0, 21, 42.
Study: NCT05052385

Intervention type: DRUG
Intervention: Ruxolitinib
Description: As per treating physician's decision - non interventional study

Intervention type: DRUG
Intervention: Ruxolitinib
Description: As per treating physician's decision - non interventional study

Intervention type: DRUG
Intervention: Ruxolitinib
Description: As per treating physician's decision - non interventional study

Intervention type: DRUG
Intervention: Ruxolitinib
Description: As per treating physician's decision - non interventional study

Intervention type: DEVICE
Intervention: Extracorporeal photopheresis
Description: As per treating physician's decision - non interventional study

Intervention type: DEVICE
Intervention: Extracorporeal photopheresis
Description: As per treating physician's decision - non interventional study

Intervention type: DEVICE
Intervention: Extracorporeal photopheresis
Description: As per treating physician's decision - non interventional study

Intervention type: DEVICE
Intervention: Extracorporeal photopheresis
Description: As per treating physician's decision - non interventional study

Intervention type: DRUG
Intervention: Ibrutinib
Description: As per treating physician's decision - non interventional study

Intervention type: DRUG
Intervention: Ibrutinib
Description: As per treating physician's decision - non interventional study
Study: NCT05795647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline+Tocopherol
Description: Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening
Study: NCT06136000

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sacral erectör spinae plane block
Description: Group S will be placed on their side. Asepsis is fifth in the transverse plane under antisepsis standards. high-frequency linear USG probe into the spinous process . The USG probe will be shifted caudally to visualize the first and second median sacral crest. The USG probe is then placed on the second medial It will be placed 3-4 cm lateral to the sacral apex and the mid-sacral apex will be imaged. On the USG screen, from top to bottom, erector spinae muscle, multifidus muscle and sacral intermediate The crest will be displayed. 0.25% bupivacaine will be administered in a total volume of 0.5ml/kg (maximum 20 cc ) by applying negative aspiration with the in-plane technique with a 50 mm Stimuplex A needle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ring Block
Description: The patient is under general anesthesia. Before the surgical procedure begins, the pediatric surgeon administers 0.5ml/kg (maximum 20cc) 0.25% bupivacaine to the base of the root of the penis with a 25-gauge needle at 3, 6, 9, and 12 o'clock.
Study: NCT05390879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation
Description: After the circuit, a 6 minutes long meditation auto-guided video.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: After the circuit, a 6 minutes long emotionally neutral video.
Study: NCT06238232

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-Pentixafor PET/CT
Description: The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET/CT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient's weight (1.85 MBq \[0.05mCi\]/kg). Local PET/CT scanning of the upper abdomen was performed on a hybrid PET/CT scanner at 10 minutes after the injection of the intravenous tracer, respectively.
Study: NCT06067386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dissemination of a selective reporting for antibiotic susceptibility testing
Description: For each E. coli positive urine culture analyzed by LabOuest, GPs will receive an antibiotic susceptibility testing report, with the list of antibiotics restricted according to four E. coli susceptibility profiles, with an emphasis on narrower-spectrum antibiotics. The selected antibiotic susceptibility testing was developed following a targeted literature review and consultation with a steering committee including GPs, biologists and infectiologists. At the GP's request, a full antibiogram can be provided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard antibiotic susceptibility testing report
Description: GPs will receive a standard antibiotic susceptibility testing report for each E. coli positive urine culture.